



Navigant

NAVIGANT CORPORATE ADVISORS LIMITED

Regd Office: 4118, Rustomjee Eaze Zone, Laxmi Singh Complex, Goregaon Mulund Link Road,
Malad West, Mumbai-400 064

Corporate Office: 423, A Wing, Bonanza, Sahar Plaza Complex, J B Nagar, Andheri-Kurla Road,
Andheri (East) Mumbai-400 059; **Tel:** +91-22- 4120 4837 / +91 22 4973 5078

Email: navigant@navigantcorp.com; **Website:** www.navigantcorp.com (CIN: L67190MH2012PLC231304)

Date: 08.02.2023

The Manager
Dept. of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai - 400 001

Dear Sir / Madam,

Sub: Submission of corrigendum to the detailed public statement in terms of SEBI SAST (Regulations), 2011 of Prism Medico and Pharmacy Limited (BSE Code: 512217)

Ref.: Open Offer to acquire upto 15,76,492 equity shares of Rs. 10/- each at a price of Rs. 11/- per fully paid-up Equity Share of Prism Medico and Pharmacy Limited ('Target Company') representing 26.00% of the fully paid -up equity and voting share capital by M/s. Symbiosis Pharmaceuticals Private Limited (Acquirer 1), M/s. Galaxy Vitacare Private Limited (Acquirer 2) and Mr. Ramit Walia (Acquirer 3) (hereinafter referred to as "the Acquirers")

Dear Sir,

This is with reference to the above please find the corrigendum to the detailed public statement in terms of SEBI SAST (Regulations), 2011 being issued by us on behalf of captioned Acquirers with regard to open offer for acquisition of Equity Shares of Prism Medico and Pharmacy Limited (Target Company) by Acquirers which was published on 08th February, 2023 in Financial Express - English Daily (all editions); Jansatta - Hindi Daily (all editions); Pratahkal - Marathi Daily (Mumbai edition); Aapka Faisla - Shimla Edition covers Sirmour.

We certify that the contents of the PDF format in soft copy are identical with the hard copy of corrigendum to the detailed public statement.

Thanks & Regards,

For Navigant Corporate Advisors Limited



Sarthak Vijlani
Managing Director

CORRIGENDUM TO THE DETAILED PUBLIC STATEMENT FOR ATTENTION TO THE SHAREHOLDERS OF PRISM MEDICO AND PHARMACY LIMITED

(CIN: L24100HP2002PLC009299)

("PMPL" / "TARGET COMPANY" / "TC")

Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173 030, India Phone No. +91-172-5020759;
Email id: investorgrievancewmcl@gmail.com; Website: www.prismmedico.in

In compliance with Regulations 3 (1) and 4 read with Regulations 15 of the SEBI (SAST) Regulations, 2011

This corrigendum to the detailed public statement is being issued by Navigant Corporate Advisors Limited, on behalf of M/s. Symbiosis Pharmaceuticals Private Limited (Acquirer 1), M/s. Galaxy Vitacare Private Limited (Acquirer 2) and Mr. Ramit Walia (Acquirer 3) in compliance with the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("**SEBI (SAST) Regulations**") and the SEBI Observation Letter no. SEBI/HO/CFD/RAC/DCR-2/P/OW/4759/1/2023 dated February 03, 2023 in respect of Open Offer ("**Offer**") for the acquisition up to 15,76,492 Equity Shares of Rs. 10/- each representing 26.00% of the total equity and voting share capital of the Target Company at a price of Rs. 11/- per share. The Detailed Public Statement ("**DPS**") pursuant to the Public Announcement ("**PA**") made by the Acquirers have appeared in Financial Express - English Daily (all editions); Jansatta - Hindi Daily (all editions); Pratahkal - Marathi Daily (Mumbai edition); Aapka Faisla – Shimla Edition covers Sirmour on December 05, 2022.

THE SHAREHOLDERS OF THE TARGET COMPANY ARE REQUESTED TO KINDLY NOTE THAT THE FOLLOWING INFORMATION RELATED TO OFFER:

1. Update in the schedule of Activities: The original and revised schedule of activities is set forth as below

Activity	Original Date	Original Day	Revised Date	Revised Day
Public Announcement	28.11.2022	Monday	28.11.2022	Monday
Publication of Detailed Public Statement in newspapers	05.12.2022	Monday	05.12.2022	Monday
Submission of Detailed Public Statement to BSE, MSEI, Target Company & SEBI	05.12.2022	Monday	05.12.2022	Monday
Last date of filing draft letter of offer with SEBI	12.12.2022	Monday	12.12.2022	Monday
Last date for a Competing offer	26.12.2022	Monday	26.12.2022	Monday
Receipt of comments from SEBI on draft letter of offer	02.01.2023	Monday	03.02.2023	Friday
Identified date	04.01.2023	Wednesday	07.02.2023	Tuesday
Date by which letter of offer be dispatched to the shareholders	11.01.2023	Wednesday	14.02.2023	Tuesday
Last date for revising the Offer Price	17.01.2023	Tuesday	20.02.2023	Monday
Comments from Committee of Independent Directors of Target Company	16.01.2023	Monday	17.02.2023	Friday
Advertisement of Schedule of activities for open offer, status of statutory and other approvals in newspapers and sending to SEBI, Stock Exchange and Target Company	17.01.2023	Tuesday	20.02.2023	Monday
Date of Opening of the Offer	18.01.2023	Wednesday	21.02.2023	Tuesday
Date of Closure of the Offer	01.02.2023	Wednesday	06.03.2023	Monday
Payment of consideration for the acquired shares	15.02.2023	Wednesday	21.03.2023	Tuesday
Final report from Merchant Banker	22.02.2023	Wednesday	29.03.2023	Wednesday

All other terms and conditions remain unchanged. Capitalized terms used in this announcement, but not defined, shall have the same meaning assigned to them in the PA, DPS and LOF.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA



Navigant

NAVIGANT CORPORATE ADVISORS LIMITED

423, A Wing, Bonanza, Sahar Plaza Complex, J B Nagar, Andheri Kurla Road, Andheri (East),
Mumbai-400 059. **Tel No.** +91 22 4120 4837 / 4973 5078

Email id: navigant@navigantcorp.com **Website:** www.navigantcorp.com

SEBI Registration No: INM000012243 **Contact person:** Mr. Sarthak Vijlani

Place: Mumbai

Date: February 07, 2023

Sunjeet Comm.